Omalizumab( A Monoclonal Anti Ig-E Antibody): Developing Biological Targeted Approach for Allergic Asthma Bronchiale
AMSA UNAIR // Faculty of Medicine, Airlangga University By: Ni Made Adnya Suasti, Kania Alawiyah, Alfian Nurfaizi, Rahmawati NurAzizah, Chabib Fachry Albab
AIM To review whether or not omalizumab works on severe asthma bronchiale and to know its effectiveness towards asthma.
BACKGROUND Intergovernmental Panel on Climate Change( IPCC) shows that the average of global temperature has increased by about 0.74 ± 0.18 ° C( 1.33 ± 0.32 ° F) in the recent 100 years [ 1 ]. The health impacts of climate change include increases in asthma, respiratory allergies, and chronic respiratory disorders [ 2 ]. Based on WHO, 235 millions people in the world suffered from asthma, 80 % is on low and middle-incomes country. According to SIRS( Sistem Informasi Rumah Sakit) in Indonesia, there are 63.584 death because of asthma [ 3 ]. The pathogenetic background is characterized by airway inflammation with infiltration of several cells( mast cells, basophils, T-helper( Th) 2lymphocytes) [ 4 ]. Government and medical professionals the prevention and treatment, but none of them working effectively when it comes to allergic asthma. Then biological targeted comes as a promising approach such as omalizumab. So we as medical students interested to review this topic.
MATERIAL AND METHODS We did a systematic review and used some e-journal sources, mostly from www. elsevier. com / locate / rmed, www. ncbi. nlm. nih. gov, and www. thelancet. com. We also use qualitative approach for the analysis.